Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer.

doi:10.1200/JCO.2016.70.3934

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Jul 2017

Petty Russell D, Dahle-Smith Asa, Stevenson David A J, Osborne Aileen, Massie Doreen, Clark Caroline, Murray Graeme I, Dutton Susan J, Roberts Corran, Chong Irene Y, Mansoor Wasat, Thompson Joyce, Harrison Mark, Chatterjee Anirban, Falk Stephen J, Elyan Sean, Garcia-Alonso Angel, Fyfe David Walter, Wadsley Jonathan, Chau Ian, Ferry David R, Miedzybrodzka Zosia

Abstract excerpt

Purpose The Cancer Esophagus Gefitinib trial demonstrated improved progression-free survival with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib relative to placebo in patients with advanced esophageal cancer who had disease progression after chemotherapy. Rapid and durable responses were observed in a minority of patients. We hypothesized that genetic aberration of the EGFR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase III as Topic

Share to Esophageal Neoplasms

Share to Gefitinib

Share to Genes, erbB-1

Share to Quinazolines

Share to Randomized Controlled Trials as Topic

Share to Single-Blind Method

Source

Open in PubMed

Identifiers

PMID: 28537764
DOI: 10.1200/JCO.2016.70.3934

Genes

EGFR
BRAF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer.PMID 28537764Read ↗

Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung CancerSemantic proximity Read ↗

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.Semantic proximity Read ↗

EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagusSemantic proximity Read ↗

Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group StudySemantic proximity Read ↗

EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.Semantic proximity Read ↗

Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.Semantic proximity Read ↗

Increased<i>HER2</i>Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor–Positive Non–Small-Cell Lung Cancer PatientsSemantic proximity Read ↗

Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer.Semantic proximity Read ↗

Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinomaSemantic proximity Read ↗

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.Semantic proximity Read ↗

EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer.Semantic proximity Read ↗

Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.